Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma

Immunotherapy

Volumn 7, Issue 6, 2015, Pages 611-619

  Johnson, Douglas B ^a   Puzanov, Igor ^a   Kelley, Mark C ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

GM CSF; HSV; immune therapy; injectable; melanoma; oncolytic; T VEC; talimogene laherperepvec

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; PEMBROLIZUMAB; TALIMOGENE LAHERPAREPVEC; VELIMOGENE ALIPLASMID; ONCOLYTIC VIRUS;

ADVANCED CANCER; ADVANCED MELANOMA; ARTICLE; CANCER IMMUNOTHERAPY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FATIGUE; FEVER; FLU LIKE SYNDROME; HUMAN; HYPOPHYSITIS; INFLAMMATION; MALAISE; MELANOMA; NAUSEA; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; VITILIGO; ANIMAL; HERPESVIRIDAE; IMMUNOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PROCEDURES;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; HERPESVIRIDAE; HUMANS; MELANOMA; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84937693906     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.35     Document Type: Article

References (50)

1. Siegel R, Ma J, Zou Z et al. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29 (2014).
2. Korn EL, Liu PY, Lee SJ et al. Meta-analysis of Phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future Phase II trials. J. Clin. Oncol. 26, 527-534 (2008).
3. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199-6206 (2009).
4. Read RL, Haydu L, Saw RP et al. In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann. Surg. Oncol. 22, 475-481 (2015).
5. Vrouenraets BC, Hart GA, Eggermont AM et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J. Am. Coll. Surg. 188, 522-530 (1999).
6. Thompson JF, Kam PC, Waugh RC et al. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin. Surg. Oncol. 14, 238-247 (1998).
7. Campana LG, Testori A, Mozzillo N et al. Treatment of metastatic melanoma with electrochemotherapy. J. Surg. Oncol. 109, 301-307 (2014).
8. Micali G, Lacarrubba F, Nasca MR et al. Topical pharmacotherapy for skin cancer: part II. Clinical applications. J. Am. Acad. Dermatol. 70, 979 e1-12; quiz 9912 (2014).
9. Robert C, Karaszewska B, Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372(1), 30-39 (2014).
10. Hodi FS, Corless CL, Giobbie-Hurder A et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J. Clin. Oncol. 31, 3182-3190 (2013).
11. Larkin J, Ascierto PA, Dreno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867-1876 (2014).
12. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
13. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
14. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
15. Morton DL, Eilber FR, Holmes EC et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann. Surg. 180, 635-643 (1974).
16. Agarwala SS, Neuberg D, Park Y et al. Mature results of a Phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 100, 1692-1698 (2004).
17. Si Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res. 6, 247-255 (1996).
18. von Wussow P, Block B, Hartmann F et al. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61, 1071-1074 (1988).
19. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim. Biophys. Acta 1785, 217-231 (2008).
20. Russell SJ, Peng KW. Viruses as anticancer drugs. Trends Pharmacol. Sci. 28, 326-333 (2007).
21. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat. Biotechnol. 30, 658-670 (2012).
22. Pol J, Bloy N, Obrist F et al. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 3, e28694 (2014).
23. Kim KH, Dmitriev IP, Saddekni S et al. A Phase I clinical trial of Ad5/3-Delta24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol. Oncol. 130, 518-524 (2013).
24. Kanerva A, Nokisalmi P, Diaconu I et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin. Cancer Res. 19, 2734-2744 (2013).
25. Park BH, Hwang T, Liu TC et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a Phase I trial. Lancet Oncol. 9, 533-542 (2008).
26. Liikanen I, Ahtiainen L, Hirvinen ML et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol. Ther. 21, 1212-1223 (2013).
27. Bramante S, Koski A, Kipar A et al. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int. J. Cancer 135, 720-730 (2014).
28. Liu BL, Robinson M, Han ZQ et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10, 292-303 (2003).
29. Mach N, Gillessen S, Wilson SB et al. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. 60, 3239-3246 (2000).
30. Broz ML, Binnewies M, Boldajipour B et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638-652 (2014).
31. Hercus TR, Thomas D, Guthridge MA et al. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood 114, 1289-1298 (2009).
32. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539-3543 (1993).
33. Hoeller C, Jansen B, Heere-Ress E et al. Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastases. J. Invest. Dermatol. 117, 371-374 (2001).
34. Kaufman HL, Ruby CE, Hughes T et al. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J. Immunother. Cancer 2, 11 (2014).
35. Toda M, Martuza RL, Rabkin SD. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol. Ther. 2, 324-329 (2000).
36. Hersey P, Gallagher S. Intralesional immunotherapy for melanoma. J. Surg. Oncol. 109, 320-326 (2014).
37. Kaufman HL, Andtbacka RHI, Collichio FA, Amatruda T, Senzer NN et al. Primary overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J. Clin. Oncol. 32, 9008-abstr (2014).
38. Zamarin D, Holmgaard RB, Subudhi SK et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 226ra32 (2014).
39. Senzer NN, Kaufman HL, Amatruda T et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27, 5763-5771 (2009).
40. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
41. Filipazzi P, Valenti R, Huber V et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25, 2546-2553 (2007).
42. Tarhini AA, Butterfield LH, Shuai Y et al. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-alpha or TLR-9 agonist and GM-CSF with peptide vaccination. J. Immunother. 35, 702-710 (2012).
43. Engeland CE, Grossardt C, Veinalde R et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol. Ther. 22, 1949-1959 (2014).
44. Puzanov I, Milhem MM, Andtbacka RH, Minor DR, Hamid O et al. Primary analysis of a Phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J. Clin. Oncol. 32, 9029-abstr. (2014).
45. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4, 101-117 (2007).
46. Bedikian AY, Richards J, Kharkevitch D et al. A Phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res. 20, 218-226 (2010).
47. Shafren DR, Au GG, Nguyen T et al. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin. Cancer Res. 10, 53-60 (2004).
48. Andtbacka RH, Shafren DR, Grose M, Post L, Weisberg J. Abstract 2939: CAVATAK-mediated oncolytic immunotherapy in advanced melanoma patients. Cancer Res. 74, 2939 (2014).
49. Toomey P, Kodumudi K, Weber A et al. Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS ONE 8, e68561 (2013).
50. Agarwala SS, Thompson JF, Smithers BM, Ross MI, Scoggins CR et al. Efficacy of intralesional Rose Bengal in patients receiving injection of all existing melanoma in Phase II study PV-10-MM-02. J. Clin. Oncol. 32, 9027 (2014).